More than 1 billion people worldwide are likely to have elevated Lp(a) but levels vary with ethnicity and gender. Professor Pia Kamstrup, Copenhagen University Hospital, Denmark discusses the evidence and its implications for cardiovascular risk in different populations.
A growing body of research supports the association between elevated Lp(a) and cardiovascular disease. Dr Anne Langsted, Rigshospitalet, Copenhagen, Denmark, considers the pivotal studies that are shaping current clinical practice and future expectations.
Until recent years, Lp(a) has lagged behind other atherogenic lipoproteins in the development of targeted lipid lowering therapies. That is now changing, as Professor Ioanna Gouni-Berthold, University of Cologne, Germany explains.
Professor Steve Nissen, Cleveland Clinic Foundation, Ohio, USA, reports data from a single ascending dose study investigating the safety and Lp(a) lowering effects of lepodisiran in patients without cardiovascular disease but with Lp(a) levels ≥75 nmol/L (≥30 mg/dL).
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
